MASI

Masimo Corp

Add to Watchlist

Advanced Chart

144.240

-1.41(-0.968%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

146.155

Open

144.390

VWAP

144.83

Vol

721.42K

Mkt Cap

7.84B

Low

143.110

Amount

104.48M

EV/EBITDA(TTM)

43.93

Total Shares

53.18M

8.38B

EV/OCF(TTM)

47.70

P/S(TTM)

3.66

Masimo Corporation is a global technology company that develops, manufactures and markets a wide array of patient monitoring technologies, as well as automation and connectivity solutions. The Company's segments include healthcare and non-healthcare. The Company’s healthcare products and patient monitoring solutions generally incorporate a monitor or circuit board, proprietary single-patient use or reusable sensors, software and/or cables. The Company primarily sells its healthcare products to hospitals, emergency medical service providers, home care providers, physician offices, veterinarians, long-term care facilities and consumers. Its measurement technologies include Measure-through Motion and Low Perfusion pulse oximetry and advanced rainbow Pulse CO-Oximetry parameters. The Company’s non-healthcare consumer business incorporates audio and home integration technologies that are primarily sold or licensed directly to consumers, or through authorized retailers and wholesalers.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

401.59M

+7.95%

1.412

+3.8%

411.70M

-31.46%

1.430

-20.56%

366.89M

-27.29%

1.201

+22.58%

Estimates Revision

The market is revising Upward the revenue expectations for Masimo Corporation (MASI) for FY2025, with the revenue forecasts being adjusted by 0.09% over the past three months. During the same period, the stock price has changed by -3.45%.

Revenue Estimates for FY2025

Revise Upward

+0.09%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+7.13%

In Past 3 Month

Stock Price

Go Down

-3.45%

In Past 3 Month

6 Analyst Rating

Wall Street analysts forecast MASI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MASI is 190.60 USD with a low forecast of 180.00 USD and a high forecast of 200.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

1 Hold

0 Sell

Strong Buy

Current: 144.240

Low

180.00

Averages

190.60

High

200.00

Current: 144.240

Low

180.00

Averages

190.60

High

200.00

Piper Sandler

Jason Bednar

Overweight

maintain

$200 -> $210

2025-08-06

Reason

Piper Sandler

Jason Bednar

Price Target

$200 -> $210

2025-08-06

maintain

Overweight

Reason

Piper Sandler analyst Jason Bednar raised the firm's price target on Masimo to $210 from $200 and keeps an Overweight rating on the shares. The firm notes the company announced Q2 revenue of $370M/+7% cc in line with Street's $369M, a minor victory considering perceived risk tied to the cybersecurity incident that negatively affected order fulfillment during May. The only question being circulated ties to incremental contracting being down year-over-year, but Piper finds it hard to give this too much negative weight when considering contract backlog still expanded nicely year-over-year.

BTIG

Buy

maintain

$183 -> $198

2025-07-14

Reason

BTIG

Price Target

$183 -> $198

2025-07-14

maintain

Buy

Reason

BTIG raised the firm's price target on Masimo to $198 from $183 and keeps a Buy rating on the shares as part of a broader research note previewing Q2 results in MedTech. Healthcare was a laggard in Q2 relative to the S&P, and early into Q3, MedTech is underperforming as fears of Medicaid cuts and hospital closures weigh on the sector following recent legislation, the analyst tells investors in a research note. The fears are likely overblown, though the earnings season is likely to offer a mixed picture as sentiment is extremely binary right now, with some companies pushing extreme valuations and others "left for dead", BTIG notes. The firm adds however that on one hand, inflation is calm, markets are at highs, and Fx has turned demonstrably favorable.

Needham

Mike Matson

Hold

Reiterates

n/a

2025-04-10

Reason

Needham

Mike Matson

Price Target

n/a

2025-04-10

Reiterates

Hold

Reason

Needham

Mike Matson

Hold

Reiterates

n/a

2025-02-26

Reason

Needham

Mike Matson

Price Target

n/a

2025-02-26

Reiterates

Hold

Reason

Wells Fargo

Vik Chopra

Buy

Maintains

$193 → $205

2025-02-26

Reason

Wells Fargo

Vik Chopra

Price Target

$193 → $205

2025-02-26

Maintains

Buy

Reason

Wells Fargo raised the firm's price target on Masimo to $205 from $193 and keeps an Overweight rating on the shares. The firm is encouraged by recent execution, gross and op margin progression and a new CEO who seems squarely focused on developing Masimo's long-term growth strategy.

Piper Sandler

Jason Bednar

Buy

Maintains

$210 → $215

2025-02-26

Reason

Piper Sandler

Jason Bednar

Price Target

$210 → $215

2025-02-26

Maintains

Buy

Reason

Piper Sandler analyst Jason Bednar raised the firm's price target on Masimo to $215 from $210 and keeps an Overweight rating on the shares. The firm notes the company announced Q4 revenue of $601M/+9% cc that was consistent with the company's preliminary release in January, while adjusted EPS finished at $1.80 on the back of strong HC operating margin. 2025 revenue guidance was reaffirmed at up 8%-11%, but management is already ratcheting higher its EPS guidance, with the midpoint shifting 25c higher just six weeks after the initial guide was provided.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Masimo Corp (MASI.O) is 26.96, compared to its 5-year average forward P/E of 42.90. For a more detailed relative valuation and DCF analysis to assess Masimo Corp 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Undervalued

5Y Average PE

42.90

Current PE

26.96

Overvalued PE

58.41

Undervalued PE

27.40

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Fair

5Y Average EV/EBITDA

25.43

Current EV/EBITDA

17.21

Overvalued EV/EBITDA

35.44

Undervalued EV/EBITDA

15.42

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

5.91

Current PS

5.05

Overvalued PS

9.44

Undervalued PS

2.37